Goldman Sachs
TGTX icon

Goldman Sachs’s TG Therapeutics TGTX Stock Holding History

Goldman Sachs’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76M Buy
2,287,688
+236,556
+12% +$7.05M 0.01% 1238
2025
Q4 		$61.1M Buy
2,051,132
+531,759
+35% +$17.4M 0.01% 1340
2025
Q3 		$54.9M Sell
1,519,373
-50,536
-3% -$1.66M 0.01% 1348
2025
Q2 		$56.5M Sell
1,569,909
-349,507
-18% -$13M 0.01% 1255
2025
Q1 		$75.7M Buy
1,919,416
+345,059
+22% +$11.6M 0.01% 946
2024
Q4 		$47.4M Sell
1,574,357
-982,070
-38% -$28.2M 0.01% 1343
2024
Q3 		$59.8M Buy
2,556,427
+471,719
+23% +$10.3M 0.01% 1114
2024
Q2 		$37.1M Buy
2,084,708
+798,280
+62% +$12.7M 0.01% 1380
2024
Q1 		$19.6M Sell
1,286,428
-363,409
-22% -$5.79M ﹤0.01% 1855
2023
Q4 		$28.2M Sell
1,649,837
-41,113
-2% -$478K 0.01% 1602
2023
Q3 		$14.1M Buy
1,690,950
+269,580
+19% +$3.76M ﹤0.01% 2085
2023
Q2 		$35.3M Buy
1,421,370
+251,868
+22% +$6.51M 0.01% 1353
2023
Q1 		$17.6M Sell
1,169,502
-46,059
-4% -$700K ﹤0.01% 1928
2022
Q4 		$14.4M Sell
1,215,561
-326,360
-21% -$2.37M ﹤0.01% 2244
2022
Q3 		$9.13M Buy
1,541,921
+587,242
+62% +$3.85M ﹤0.01% 2597
2022
Q2 		$4.06M Sell
954,679
-377,723
-28% -$2.36M ﹤0.01% 3350
2022
Q1 		$12.7M Buy
1,332,402
+217,336
+19% +$2.52M ﹤0.01% 2453
2021
Q4 		$21.2M Buy
1,115,066
+9,191
+0.8% +$239K ﹤0.01% 2064
2021
Q3 		$36.8M Buy
1,105,875
+397,894
+56% +$12.3M 0.01% 1524
2021
Q2 		$27.5M Sell
707,981
-621,399
-47% -$24.4M 0.01% 1772
2021
Q1 		$64.1M Buy
1,329,380
+102,953
+8% +$4.95M 0.02% 962
2020
Q4 		$63.8M Sell
1,226,427
-50,598
-4% -$1.71M 0.02% 928
2020
Q3 		$34.2M Buy
1,277,025
+151,626
+13% +$3.49M 0.01% 1300
2020
Q2 		$21.9M Buy
1,125,399
+35,524
+3% +$572K 0.01% 1609
2020
Q1 		$10.7M Sell
1,089,875
-130,647
-11% -$1.65M ﹤0.01% 2041
2019
Q4 		$13.5M Buy
1,220,522
+163,769
+15% +$1.25M ﹤0.01% 2198
2019
Q3 		$5.93M Buy
1,056,753
+123,251
+13% +$859K ﹤0.01% 2722
2019
Q2 		$8.07M Sell
933,502
-7,154
-0.8% -$54.1K ﹤0.01% 2518
2019
Q1 		$7.56M Buy
940,656
+178,071
+23% +$962K ﹤0.01% 2653
2018
Q4 		$3.13M Buy
762,585
+384,274
+102% +$1.91M ﹤0.01% 3253
2018
Q3 		$2.12M Buy
378,311
+15,130
+4% +$173K ﹤0.01% 3565
2018
Q2 		$4.78M Buy
363,181
+19,153
+6% +$263K ﹤0.01% 2996
2018
Q1 		$4.88M Buy
344,028
+32,235
+10% +$412K ﹤0.01% 2907
2017
Q4 		$2.56M Buy
311,793
+290,066
+1,335% +$2.53M ﹤0.01% 3577
2017
Q3 		$257K Buy
+21,727
New +$247K ﹤0.01% 5587
2017
Q2 		– Sell
-43,020
Closed -$501K – 6967
2017
Q1 		$501K Buy
43,020
+26,001
+153% +$187K ﹤0.01% 5033
2016
Q4 		$79K Buy
17,019
+5,580
+49% +$32.7K ﹤0.01% 6247
2016
Q3 		$89K Buy
+11,439
New +$73.6K ﹤0.01% 6284
2015
Q3 		– Sell
-43,053
Closed -$714K – 7491
2015
Q2 		$714K Buy
43,053
+17,501
+68% +$277K ﹤0.01% 4857
2015
Q1 		$396K Buy
+25,552
New +$387K ﹤0.01% 5366
2014
Q3 		– Sell
-10,282
Closed -$97K – 7256
2014
Q2 		$97K Buy
+10,282
New +$65.7K ﹤0.01% 6560
2013
Q3 		– Sell
-113,299
Closed -$724K – 6702
2013
Q2 		$724K Buy
+113,299
New +$726K ﹤0.01% 4649

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's TGTX Position: Q1 2026 in Review

Goldman Sachs increased its TG Therapeutics (TGTX) stake by 12% in Q1 2026, buying an estimated $7.05M and bringing the position to 2,287,688 shares worth $76M. The position accounts for 0.01% of the portfolio, ranked #1238.

Goldman Sachs first reported a position in TGTX in Q2 2013 and has held it in 42 quarters since. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Goldman Sachs held 2,287,688 shares of TG Therapeutics worth $76M as of Q1 2026.
  • Goldman Sachs bought 236,556 TG Therapeutics shares in Q1 2026, an estimated $7.05M.
  • TG Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1238 holding.
  • Goldman Sachs first reported a position in TG Therapeutics in Q2 2013 and has held it in 42 quarters since.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.